Last reviewed · How we verify
Pilocarpine HCl
Pilocarpine HCl is a muscarinic acetylcholine receptor agonist that stimulates parasympathetic activity to increase salivary and lacrimal gland secretion.
Pilocarpine HCl is a muscarinic acetylcholine receptor agonist that stimulates parasympathetic activity to increase salivary and lacrimal gland secretion. Used for Xerostomia (dry mouth) in patients with Sjögren's syndrome, Xerophthalmia (dry eyes), Radiation-induced xerostomia.
At a glance
| Generic name | Pilocarpine HCl |
|---|---|
| Also known as | AGN-190584 |
| Sponsor | Allergan |
| Drug class | Muscarinic receptor agonist |
| Target | Muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Otolaryngology |
| Phase | Phase 3 |
Mechanism of action
Pilocarpine binds to and activates muscarinic M3 receptors on salivary and lacrimal glands, mimicking the effects of acetylcholine and promoting fluid secretion. This mechanism is used to treat xerostomia (dry mouth) and xerophthalmia (dry eyes) by directly stimulating residual gland function. The drug's parasympathomimetic effects increase both salivary flow and tear production.
Approved indications
- Xerostomia (dry mouth) in patients with Sjögren's syndrome
- Xerophthalmia (dry eyes)
- Radiation-induced xerostomia
Common side effects
- Increased sweating
- Nausea
- Headache
- Dizziness
- Urinary frequency
- Lacrimation
Key clinical trials
- Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia (PHASE3)
- Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function (NA)
- Pilocarpine Use After Kahook Goniotomy (PHASE3)
- Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia (PHASE2)
- Optimal Treatment Protocol for Selective Laser Trabeculoplasty (NA)
- Optimal Treatment Protocol for Selective Laser Trabeculoplasty - Repeat Trial (NA)
- Evaluation of NV701 (Pilocarpine 1.25%) Compared With Vuity (Pilocarpine 1.25%) on Pupil Size in Subjects With Presbyopia (EARLY_PHASE1)
- Quality of Life in Presbyopic Patients Who Are Treated With Qlosi (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pilocarpine HCl CI brief — competitive landscape report
- Pilocarpine HCl updates RSS · CI watch RSS
- Allergan portfolio CI